Qiagen (QGEN) Barclays 28th Annual Global Healthcare Conference summary

Strategic direction and leadership transition

• CEO search is progressing with a shortlist of US and European candidates, and an announcement expected in Q2; the transition is viewed as an opportunity to review and strengthen strategic direction.

• The board is open to all strategic alternatives, including organic growth, acquisitions, or potential transactions to enhance shareholder value, and has hired advisors to assist.

• Committed to solid profitable growth, targeting at least $2 billion in net sales from growth pillars by 2028 and ≥31% adjusted operating income margin at constant exchange rates.

• Ongoing disciplined capital allocation, with over $1 billion in returns to shareholders planned for 2024–2028, excluding M&A.

• ESG initiatives include a net zero carbon emission target by 2050 and top-tier ESG ratings.

Financial guidance and performance

• Full-year guidance targets 5% growth, with FY 2025 net sales reaching $2.09 billion (+5% CER) and adjusted diluted EPS of $2.38, both at or above outlook.

• Adjusted operating income margin improved to 29.5% in FY 2025, with a midterm target of 31% for 2028 and potential for further increases after CEO review.

• FY 2026 outlook projects ≥5% CER net sales growth and adjusted diluted EPS of ≥$2.50, driven by ~9% CER expansion from growth pillars.

• Operating cash flow for FY 2025 was $654 million, supporting higher CAPEX for IT infrastructure; free cash flow was $453 million, with a leverage ratio of 0.7x.

• Margin expansion driven by growth in consumables, improved gross margin, and efficiency initiatives, including ERP system integration and site consolidation.

Market environment and customer reach

• Macroeconomic challenges and customer caution, especially in automation investments, persist; US NIH budget approval is positive for consumables, but confidence for large capital investments remains low.

• Middle East instability is impacting logistics and costs; academic and government funding remains slow to release, but consumables are resilient.

• Over 5,700 employees and more than 500,000 customers worldwide, with balanced sales across Americas (52%), EMEA (34%), and Asia-Pacific/Japan (14%).

• Increased requests for quotes for new instruments in the US signal optimism for H2.

• QDI (QIAGEN Digital Insights) serves over 150,000 users in 90+ countries, with SaaS transition and AI integration accelerating.